Changeflow GovPing Pharma & Drug Safety Composition Comprising Lactic Acid Bacteria Der...
Routine Rule Added Final

Composition Comprising Lactic Acid Bacteria Derived from Green Tea for Improving Liver Function

Favicon for changeflow.com USPTO Patent Grants - Pharma (A61K)
Published
Detected
Email

Summary

USPTO granted patent US12594310B2 to AMOREPACIFIC CORPORATION on April 7, 2026, covering a method for improving hepatic function using a composition derived from green tea-derived Lactiplantibacillus plantarum strain. The patent includes 6 claims and covers the strain, culture, lysate, and extracts thereof.

What changed

USPTO issued patent grant US12594310B2 to AMOREPACIFIC CORPORATION for a composition and method utilizing a green tea-derived Lactiplantibacillus plantarum strain to improve liver function. The patent claims cover the bacterial strain itself, cultures thereof, lysates, and various extracts from the strain or its culture. The filing date was May 8, 2023, with application number 18313465.

The grant provides AMOREPACIFIC CORPORATION with exclusive rights to the patented composition and method in the United States. Competitors in the functional food, dietary supplement, and pharmaceutical sectors must avoid infringing these claims when developing similar probiotic liver health products. Parties interested in licensing this technology or designing around the patent should review the full claim scope.

What to do next

  1. Monitor for updates

Archived snapshot

Apr 7, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Grants

Composition comprising lactic acid bacteria derived from green tea for improving liver function

Grant US12594310B2 Kind: B2 Apr 07, 2026

Assignee

AMOREPACIFIC CORPORATION

Inventors

Hyun Woo Jeong, Donghyun Cho, Wanki Kim, Jong Hwa Roh

Abstract

A method for improving hepatic function, including administering an effective amount of a composition including a green tea-derived Lactiplantibacillus plantarum strain; a culture of the strain; a lysate of the strain; an extract of the strain; an extract of the culture; or an extract of the lysate to a subject in need thereof is disclosed in the specification.

CPC Classifications

A61P 1/16 A61K 35/747 A61K 36/82

Filing Date

2023-05-08

Application No.

18313465

Claims

6

View original document →

Get daily alerts for USPTO Patent Grants - Pharma (A61K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 7th, 2026
Instrument
Rule
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
US12594310B2

Who this affects

Applies to
Manufacturers Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent grants IP licensing Probiotic formulation
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Healthcare

Get alerts for this source

We'll email you when USPTO Patent Grants - Pharma (A61K) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!